Microdosing vs. SSRIs: What the Evidence Actually Shows

Why This Comparison Keeps Coming Up

That number alone explains why "microdosing vs SSRIs" has become one of the most searched comparisons in this space. People are not asking out of idle curiosity. They are asking because something about their current approach is not working well enough, or because they want to understand their options more fully.

Many of you reading this are likely already taking an SSRI. Perhaps it helped for a while. Perhaps the side effects feel like a steep price. Perhaps you have read promising headlines about psilocybin and want to know whether microdosing could offer something different. These are reasonable questions, and they deserve an honest answer rather than cheerleading for either side.

This article is not here to tell you which option is better. It is here to lay out what the evidence actually shows for both, where the gaps are, and what matters when thinking about your own situation. Because the honest truth is that these two approaches have very different evidence bases, very different legal statuses, and very different risk profiles. Pretending otherwise would not serve you.

SSRIs: What We Know After Decades of Use

Selective serotonin reuptake inhibitors have been prescribed since fluoxetine (Prozac) was approved in 1987. They work by blocking the reabsorption of serotonin in the brain, increasing its availability in the synaptic cleft. This is the most widely prescribed class of antidepressants globally, with an estimated 13% of adults in the US taking one in any given month (NCHS Data Brief, 2020).

The evidence base is substantial. A landmark 2018 meta-analysis by Cipriani et al., published in The Lancet, analysed 522 randomised controlled trials involving 116,477 participants and found that all 21 antidepressants studied were more effective than placebo for acute treatment of major depressive disorder. SSRIs specifically showed consistent efficacy for moderate to severe depression and several anxiety disorders. This is the kind of evidence base that takes decades and billions in funding to build.

But "effective on average" does not mean "works perfectly for everyone.". Side effects are well documented and sometimes significant:, emotional blunting is reported by around 46%, and weight gain and sleep disruption are common. Discontinuation syndrome, sometimes called withdrawal, can be prolonged and distressing, particularly after long-term use.

None of this makes SSRIs a bad treatment. It makes them what they are: a legitimate, imperfect medical intervention that helps many people and does not work well for others.

Microdosing: What We Know So Far

First, an important distinction. The clinical trials making headlines about psilocybin and depression, such as the 2021 trial by Carhart-Harris et al. comparing psilocybin-assisted therapy to escitalopram, use full therapeutic doses (typically 10 to 25mg) in controlled clinical settings with extensive psychological support. These are not microdosing studies. The evidence for full-dose psilocybin-assisted therapy is promising and growing. The evidence for microdosing specifically is much earlier in its development.

The most rigorous microdosing study to date is the 2022 self-blinding trial led by Szigeti et al. at Imperial College London, published in eLife. It involved 191 participants who were already microdosing and used an innovative self-blinding protocol. The finding: microdosing did improve psychological wellbeing, but so did placebo, with no significant difference between the two groups. This does not prove microdosing does nothing. It suggests that expectancy effects, the belief that you are taking something beneficial, are a powerful confound that is difficult to separate from genuine pharmacological effects.

A 2022 randomised controlled trial at the University of Auckland (Marschall et al., Translational Psychiatry) found that low-dose psilocybin (1mg, 3mg) did not significantly outperform placebo on measures of wellbeing or creativity over a six-week period in 34 healthy adults. Again, some positive signals, but not the clear separation from placebo that would constitute strong evidence.

Large observational studies paint a more encouraging picture. A 2021 study by Rootman et al. in Scientific Reports, tracking 8,703 participants, found that microdosers reported lower levels of anxiety and depression compared to non-microdosers. But observational data cannot establish causation. People who choose to microdose may differ from those who do not in ways that affect outcomes independently.

Head to Head: Comparing the Evidence

Comparing SSRIs and microdosing is a bit like comparing a medication with 35 years of clinical data to a practice with perhaps five years of formal research attention. The comparison is worth making, but only if we are honest about the asymmetry.

Strength of Clinical Evidence

SSRIs have hundreds of large-scale RCTs, extensive meta-analyses, and regulatory approval from agencies including the FDA, EMA, and MHRA. Dosing, interactions, contraindications, and long-term effects have been studied in millions of patients over decades.

Microdosing has a handful of controlled trials, most with small sample sizes, and no regulatory approval anywhere in the world for any indication. The bulk of the evidence comes from surveys, observational studies, and anecdotal reports. This gap is not a judgement on microdosing's potential. It is a reflection of where the research currently stands.

Reported Benefits and Mechanisms

SSRIs primarily target symptom reduction in depression and anxiety through serotonin reuptake inhibition, gradually increasing serotonin availability over weeks. Microdosing, by contrast, involves sub-perceptual doses of psilocybin (or sometimes LSD), which acts as a 5-HT2A receptor agonist. Research on full-dose psilocybin suggests potential neuroplasticity effects, including increased dendritic spine density (Shao et al., 2021). Whether microdoses produce similar neuroplastic changes remains unclear. For a deeper look at proposed mechanisms, see our article on the neuroscience of microdosing.

The qualitative character of reported benefits tends to differ too. People on SSRIs often describe a reduction in the intensity of negative emotions. People who microdose frequently report enhanced emotional openness, creative flexibility, and a sense of connection. These are different kinds of outcomes, and they may reflect fundamentally different pharmacological approaches even though both involve the serotonin system.

Side Effect Profiles

SSRI side effects are well catalogued through decades of post-market surveillance. As noted above, sexual dysfunction, emotional blunting, weight changes, and discontinuation effects are common and well documented.

Microdosing side effects are less studied, but emerging data points to real concerns. Survey data and anecdotal reports suggest microdosing side effects can include anxiety amplification, sleep disruption, emotional intensity, and physiological discomfort including headaches and nausea. There are also open questions about cardiac safety with repeated 5-HT2B agonism. The absence of well-documented side effects is not the same as safety. It often simply means the research has not been done yet.

Accessibility and Legal Status

SSRIs are legally prescribed and available worldwide. Psilocybin remains a controlled substance in most jurisdictions, classified as Schedule I in the US and Class A in the UK. This is not a minor footnote. It affects quality control, consistency of dose, medical oversight, and legal risk. For an overview of how regulations vary, see our article on the legal landscape of microdosing. Legal status varies by jurisdiction, and it is your responsibility to understand the laws where you live.

The Serotonin Syndrome Question

This section matters enough to stand on its own. If you are currently taking an SSRI and considering microdosing, you need to understand the risk of serotonin syndrome.

Serotonin syndrome occurs when excessive serotonergic activity overwhelms the nervous system. Symptoms range from mild (agitation, tremor, diarrhoea) to life-threatening (hyperthermia, seizures, cardiovascular instability). It typically results from combining two or more serotonergic substances. Both SSRIs and psilocybin act on the serotonin system, albeit through different mechanisms.

The clinical data on this specific combination at microdose levels is limited. Some researchers suggest that the risk at sub-perceptual doses is lower than at full therapeutic doses, and SSRIs may actually blunt the effects of psilocybin by competing at serotonin receptors. But "probably lower risk" is not the same as "safe," and case reports of adverse interactions do exist. We cover this in much more detail in our dedicated articles on microdosing and SSRIs and medication interactions.

What This Comparison Cannot Tell You

It would be convenient if this article could end with a clear verdict. It cannot, and any article that does is oversimplifying.

SSRIs and microdosing are not equivalent options sitting on a shelf for you to choose between. One is a regulated medical treatment with decades of evidence. The other is an emerging practice with promising but preliminary research and significant legal restrictions. Your individual biology, mental health history, severity of symptoms, current medications, and where you live all shape which options are even available to you, let alone advisable.

Microdosing is not a validated clinical treatment for depression or anxiety. It may become one, or some version of psilocybin therapy may. But right now, framing it as a simple swap for SSRIs is misleading and potentially dangerous. Equally, it would be dishonest to pretend SSRIs work well for everyone or that their side effects are trivial. Many people have legitimate reasons for exploring alternatives.

The most dangerous path is the one taken without guidance: stopping SSRIs abruptly, without medical supervision, because of something read online. SSRI discontinuation syndrome can involve severe mood destabilisation, rebound depression, and physical symptoms lasting weeks or months. If you are considering any change to your treatment, please involve your prescribing clinician. For more on who should not microdose, our contraindications guide is a good starting point.

Questions Worth Asking Yourself (and Your Provider)

Before making any decision, it helps to get clear on what you are actually looking for. These questions are not a diagnostic tool. They are reflection prompts designed to slow down the decision-making process and bring more honesty into it.

• What am I hoping to change? Symptom severity? Emotional range? A sense of disconnection? Naming what you want can clarify which approach is more likely to address it.
• Am I considering this because my current treatment is genuinely not working, or because of something I read online? Both are valid starting points, but they lead to different conversations with your provider.
• Have I spoken honestly with a healthcare provider about my goals? Including the parts that feel awkward, like wanting to try something they might not endorse?
• Am I in a stable enough place to experiment with my approach? Periods of acute crisis are generally not the right time to make significant changes to medication or introduce new practices.
• What does my own data tell me? How have I actually been feeling, not just how I remember feeling? Patterns are easier to see with consistent tracking.

Clarify your intentions before making changes. Afterglow's journaling and pattern-tracking tools help you build a clear picture of how you are actually feeling, useful data to bring into any conversation with a healthcare provider.

Writing these reflections down, rather than letting them loop in your head, often reveals something you did not expect. Whether you are considering microdosing, adjusting an existing prescription, or simply trying to understand your options, structured self-reflection is a practical first step.

Where the Research May Go Next

The microdosing research landscape is moving quickly. Several rigorous RCTs are underway or planned, including larger trials at institutions like Maastricht University and the University of Chicago. The Beckley Foundation continues to fund controlled studies examining cognitive and emotional effects of low-dose psychedelics. As these trials report results over the coming years, our understanding of what microdosing does and does not do will sharpen considerably.

There is also growing interest in comparative studies, research that directly examines how microdosing stacks up against established treatments in controlled settings. These are exactly the kinds of studies the field needs, but they take time, funding, and regulatory cooperation to execute well.

Stay grounded as the science evolves. Afterglow helps you track your own experience with structure and intention, so your understanding grows alongside the research.

For now, the most responsible position is honest curiosity paired with appropriate caution. The evidence base for microdosing is not yet strong enough to recommend it as a replacement for established treatments. But it is substantive enough to take seriously and to watch closely. Stay curious. Stay grounded. And update your understanding as new data emerges, rather than locking into a position based on today's incomplete picture.

References

• Cipriani, A. et al.. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder. The Lancet, 391(10128), 1357-1366.
• Carhart-Harris, R. et al.. Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine, 384, 1402-1411.
• Rootman, J.M. et al.. Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression. Scientific Reports, 11, 22479.
• Shao, L.X. et al.. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron, 109(16), 2535-2544.
• NCHS Data Brief No. 377. Antidepressant use among adults: United States, 2015-2018. CDC/National Center for Health Statistics.